DK3067064T3 - Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf - Google Patents
Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf Download PDFInfo
- Publication number
- DK3067064T3 DK3067064T3 DK16166033.7T DK16166033T DK3067064T3 DK 3067064 T3 DK3067064 T3 DK 3067064T3 DK 16166033 T DK16166033 T DK 16166033T DK 3067064 T3 DK3067064 T3 DK 3067064T3
- Authority
- DK
- Denmark
- Prior art keywords
- proteins
- procedures
- modified rsv
- rsv
- modified
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18523—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12112608P | 2008-12-09 | 2008-12-09 | |
US16907709P | 2009-04-14 | 2009-04-14 | |
US22478709P | 2009-07-10 | 2009-07-10 | |
EP09836751.9A EP2370099B1 (en) | 2008-12-09 | 2009-12-09 | Modified rsv f proteins and methods of their use |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3067064T3 true DK3067064T3 (da) | 2020-06-08 |
Family
ID=42310119
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09836751.9T DK2370099T3 (da) | 2008-12-09 | 2009-12-09 | Modificerede rsv f-proteiner og fremgangsmåder til deres anvendelse |
DK16166033.7T DK3067064T3 (da) | 2008-12-09 | 2009-12-09 | Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09836751.9T DK2370099T3 (da) | 2008-12-09 | 2009-12-09 | Modificerede rsv f-proteiner og fremgangsmåder til deres anvendelse |
Country Status (23)
Country | Link |
---|---|
US (7) | US8715692B2 (da) |
EP (3) | EP3718566B1 (da) |
JP (4) | JP5813513B2 (da) |
KR (2) | KR101801213B1 (da) |
CN (2) | CN102307591B (da) |
AU (1) | AU2009333484B2 (da) |
BR (1) | BRPI0922867B8 (da) |
CA (1) | CA2746228C (da) |
CY (2) | CY1117757T1 (da) |
DK (2) | DK2370099T3 (da) |
ES (2) | ES2796725T3 (da) |
HK (1) | HK1161690A1 (da) |
HR (2) | HRP20160859T1 (da) |
HU (2) | HUE051666T2 (da) |
IL (2) | IL213450B (da) |
LT (1) | LT3067064T (da) |
MX (4) | MX358836B (da) |
PL (2) | PL3067064T3 (da) |
PT (2) | PT2370099T (da) |
RU (1) | RU2531510C2 (da) |
SG (2) | SG172022A1 (da) |
SI (2) | SI2370099T1 (da) |
WO (1) | WO2010077717A1 (da) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160000902A1 (en) * | 2003-07-11 | 2016-01-07 | Novavax, Inc. | Combination vaccine for respiratory syncytial virus and influenza |
CA2743012A1 (en) * | 2008-11-18 | 2010-05-27 | Ligocyte Pharmaceuticals, Inc. | Rsv f vlps and methods of manufacture and use thereof |
PL3067064T3 (pl) | 2008-12-09 | 2020-11-02 | Novavax, Inc. | Zmodyfikowane białka f rsv i sposoby ich wykorzystania |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
EP3988115A3 (en) * | 2009-07-15 | 2022-08-17 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
WO2011046925A1 (en) * | 2009-10-12 | 2011-04-21 | Technovax, Inc. | Respiratory syncytial virus (rsv) virus-like particles (vlps) |
JP6158088B2 (ja) | 2010-11-05 | 2017-07-05 | ノババックス,インコーポレイテッド | 狂犬病糖タンパク質ウイルス様粒子(vlp) |
WO2012089231A1 (en) * | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
ES2727836T3 (es) | 2011-01-26 | 2019-10-21 | Glaxosmithkline Biologicals Sa | Régimen de inmunización del VRS |
WO2013019800A1 (en) * | 2011-08-01 | 2013-02-07 | Emory University | Vlps containing ligands and methods related thereto |
US9463236B2 (en) | 2011-08-29 | 2016-10-11 | Tokushima University | RSV mucosal vaccine |
EP2760469A4 (en) * | 2011-09-30 | 2015-03-18 | Novavax Inc | RECOMBINANT RSV-F NANOPARTICLE VACCINE AGAINST RESPIRATORY SYNZYTIAL VIRUS |
CN103239734B (zh) * | 2012-02-10 | 2016-02-24 | 北京艾棣维欣生物技术有限公司 | 用于预防和/或治疗呼吸道合胞病毒感染的疫苗 |
EP3656396A1 (en) * | 2012-08-01 | 2020-05-27 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
KR20150085843A (ko) | 2012-11-20 | 2015-07-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Rsv f 융합전 삼합체 |
AU2014214590A1 (en) * | 2013-02-11 | 2015-08-27 | Novavax, Inc. | Combination vaccine for respiratory syncytial virus and influenza |
DE102013004595A1 (de) * | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
WO2015042373A1 (en) | 2013-09-19 | 2015-03-26 | Novavax, Inc. | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
US10100372B2 (en) | 2014-06-18 | 2018-10-16 | Georgia State University Research Foundation, Inc. | Recombinant RSV reporter virus |
JP6824154B2 (ja) * | 2014-08-08 | 2021-02-03 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC | 修飾エンベロープタンパク質e3を含むウイルス様粒子 |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
KR102638978B1 (ko) | 2015-07-07 | 2024-02-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
KR20240093593A (ko) | 2015-09-03 | 2024-06-24 | 노바백스, 인코포레이티드 | 개선된 안정성 및 면역원성을 갖는 백신 조성물 |
MX2018007622A (es) | 2015-12-23 | 2018-11-14 | Pfizer | Mutantes de proteina f de rsv. |
US10729757B2 (en) | 2016-04-05 | 2020-08-04 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
CA3025441A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
CN106011086A (zh) * | 2016-06-15 | 2016-10-12 | 湖北省农业科学院畜牧兽医研究所 | 表达信号肽替换的呼吸道合胞病毒f蛋白的重组新城疫耐热疫苗株及制备方法 |
EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS VACCINE |
WO2018176103A1 (en) * | 2017-03-30 | 2018-10-04 | The University Of Queensland | "chimeric molecules and uses thereof" |
CN115947873A (zh) | 2017-04-04 | 2023-04-11 | 华盛顿大学 | 显示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途 |
CN110891592B (zh) | 2017-06-14 | 2024-08-13 | 维罗米蒂克斯股份公司 | 用于保护免受呼吸道合胞病毒的环状肽 |
EP3658118A4 (en) | 2017-07-24 | 2021-03-31 | Novavax, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF RESPIRATORY DISEASES |
WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
AU2019228551A1 (en) | 2018-02-28 | 2020-10-15 | University Of Washington | Self-assembling nanostructure vaccines |
IL277274B2 (en) | 2018-03-19 | 2024-02-01 | Novavax Inc | Multifunctional nanoparticle vaccines for influenza |
US11576960B2 (en) * | 2018-03-30 | 2023-02-14 | Georgia State University Research Foundation, Inc. | Respiratory syncytial virus (RSV) vaccines |
KR20210018206A (ko) | 2018-04-03 | 2021-02-17 | 사노피 | 항원성 호흡기 세포융합 바이러스 폴리펩타이드 |
KR20200050264A (ko) | 2018-11-01 | 2020-05-11 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
CA3121724A1 (en) | 2018-12-20 | 2020-06-25 | Virometix Ag | Lipopeptide building blocks and synthetic virus-like particles |
EP3932424A4 (en) | 2019-02-28 | 2022-10-12 | KM Biologics Co., Ltd. | F/G CHIMERIC VRS VACCINE |
US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
IL295142A (en) * | 2020-01-27 | 2022-09-01 | Novavax Inc | Formulations for the vaccine against the corona virus |
IL297419B1 (en) | 2020-04-22 | 2024-10-01 | BioNTech SE | Vaccine against the corona virus |
CN113855796B (zh) * | 2021-07-30 | 2024-01-26 | 河北医科大学 | 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用 |
WO2023062651A1 (en) * | 2021-10-13 | 2023-04-20 | Padmanabh Patil Harshad | Virus-like particles for respiratory syncytial virus and method of preparation thereof |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
CN115927751A (zh) * | 2022-09-17 | 2023-04-07 | 宁夏大学 | 牛呼吸道合胞体病毒实时荧光定量pcr检测的引物探针组及检测方法 |
WO2024193380A1 (zh) * | 2023-03-17 | 2024-09-26 | 成都威斯克生物医药有限公司 | 抗呼吸道合胞病毒感染的疫苗 |
CN118146321B (zh) * | 2024-03-27 | 2024-08-27 | 普大生物科技(泰州)有限公司 | 一种rsv重组蛋白疫苗及其制备方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
GB8914968D0 (en) * | 1989-06-29 | 1989-08-23 | Connaught Lab | Production of virus and purification of viral envelope proteins for vaccine use |
US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
ES2370937T3 (es) | 1993-09-13 | 2011-12-23 | Protein Sciences Corporation | Un método para producir vacunas antigripales polivalentes a base de hemaglutinina. |
US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
US6020182A (en) * | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
WO2001066137A1 (en) | 2000-03-07 | 2001-09-13 | Merck & Co., Inc. | Adenovirus formulations |
WO2002028426A1 (en) | 2000-10-02 | 2002-04-11 | Glaxosmithkline Biologicals S.A. | Split enveloped virus preparation |
US7041500B2 (en) | 2002-02-14 | 2006-05-09 | Novavax, Inc. | Insect cell line |
KR101187955B1 (ko) | 2003-04-25 | 2012-10-08 | 비로노바티브 비브이 | 메타뉴모바이러스 유래 이종 항원을 포함하는 재조합파라인플루엔자 바이러스 발현 시스템 및 백신 |
CA2529710A1 (en) * | 2003-06-20 | 2005-03-10 | Protein Sciences Corporation | Vectors expressing sars immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using |
US7588770B2 (en) | 2003-12-10 | 2009-09-15 | The Uab Research Foundation | Recombinant viruses of the paramyxoviridae family with heterologous envelope glycoproteins |
JP2008537482A (ja) | 2005-03-10 | 2008-09-18 | メッドイミューン バクシーンズ,インコーポレイティド | メタニューモウイルス株、およびワクチン製剤におけるその使用および抗原配列発現用ベクターとしてのその使用、ならびにウイルスの増殖法 |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
CA2655929A1 (en) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins |
US20080233150A1 (en) * | 2006-11-16 | 2008-09-25 | Gale Smith | Respiratory syncytial virus-virus like particle (vlps) |
EP2099486A2 (en) * | 2006-11-30 | 2009-09-16 | Government Of The United States Of America, As Represented by the Secretary | Codon modified immunogenic compositions and methods of use |
EP1972348A1 (en) * | 2007-03-14 | 2008-09-24 | Pierre Fabre Medicament | Novel vaccine composition for the treatment of respiratory infectious diseases |
CA2684578A1 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
US20110008838A1 (en) | 2007-07-19 | 2011-01-13 | Gale Smith | Chimeric varicella zoster virus virus-like particles |
EP3508505A1 (en) | 2007-12-24 | 2019-07-10 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
MX2010009351A (es) | 2008-02-25 | 2011-03-04 | Novavax Inc | Particulas similares a virus cristalizadas con azucar. |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
PL3067064T3 (pl) | 2008-12-09 | 2020-11-02 | Novavax, Inc. | Zmodyfikowane białka f rsv i sposoby ich wykorzystania |
EA201791383A1 (ru) | 2009-05-27 | 2018-06-29 | Селекта Байосайенсиз, Инк. | Наноносители, имеющие компоненты с различными скоростями высвобождения |
ES2583257T3 (es) * | 2009-06-24 | 2016-09-20 | Glaxosmithkline Biologicals S.A. | Antígenos recombinantes del VSR |
EP3988115A3 (en) | 2009-07-15 | 2022-08-17 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
JP6158088B2 (ja) | 2010-11-05 | 2017-07-05 | ノババックス,インコーポレイテッド | 狂犬病糖タンパク質ウイルス様粒子(vlp) |
JP2014520807A (ja) * | 2011-07-06 | 2014-08-25 | ノバルティス アーゲー | 免疫原性組成物およびその使用 |
EP2760469A4 (en) | 2011-09-30 | 2015-03-18 | Novavax Inc | RECOMBINANT RSV-F NANOPARTICLE VACCINE AGAINST RESPIRATORY SYNZYTIAL VIRUS |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
AU2014214590A1 (en) | 2013-02-11 | 2015-08-27 | Novavax, Inc. | Combination vaccine for respiratory syncytial virus and influenza |
CA2910067C (en) | 2013-04-25 | 2023-10-17 | Crucell Holland B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
AU2014100888A4 (en) | 2014-08-07 | 2014-09-11 | Novartis Ag | Virus clearance and protein purification methods |
WO2017000105A1 (zh) * | 2015-06-29 | 2017-01-05 | 尚平 | 便携式加湿器 |
KR20240093593A (ko) | 2015-09-03 | 2024-06-24 | 노바백스, 인코포레이티드 | 개선된 안정성 및 면역원성을 갖는 백신 조성물 |
-
2009
- 2009-12-09 PL PL16166033T patent/PL3067064T3/pl unknown
- 2009-12-09 SG SG2011041696A patent/SG172022A1/en unknown
- 2009-12-09 MX MX2017001924A patent/MX358836B/es unknown
- 2009-12-09 CN CN200980156344.9A patent/CN102307591B/zh active Active
- 2009-12-09 KR KR1020167035029A patent/KR101801213B1/ko active IP Right Grant
- 2009-12-09 MX MX2011006205A patent/MX2011006205A/es active IP Right Grant
- 2009-12-09 AU AU2009333484A patent/AU2009333484B2/en active Active
- 2009-12-09 LT LTEP16166033.7T patent/LT3067064T/lt unknown
- 2009-12-09 HU HUE16166033A patent/HUE051666T2/hu unknown
- 2009-12-09 DK DK09836751.9T patent/DK2370099T3/da active
- 2009-12-09 EP EP20171841.8A patent/EP3718566B1/en active Active
- 2009-12-09 BR BRPI0922867A patent/BRPI0922867B8/pt active IP Right Grant
- 2009-12-09 DK DK16166033.7T patent/DK3067064T3/da active
- 2009-12-09 MX MX2014011966A patent/MX337932B/es unknown
- 2009-12-09 JP JP2011540854A patent/JP5813513B2/ja active Active
- 2009-12-09 WO PCT/US2009/067269 patent/WO2010077717A1/en active Application Filing
- 2009-12-09 MX MX2016003771A patent/MX345700B/es unknown
- 2009-12-09 SG SG10201500161XA patent/SG10201500161XA/en unknown
- 2009-12-09 EP EP16166033.7A patent/EP3067064B1/en active Active
- 2009-12-09 SI SI200931470A patent/SI2370099T1/sl unknown
- 2009-12-09 PL PL09836751.9T patent/PL2370099T3/pl unknown
- 2009-12-09 PT PT98367519T patent/PT2370099T/pt unknown
- 2009-12-09 ES ES16166033T patent/ES2796725T3/es active Active
- 2009-12-09 CN CN201610520252.6A patent/CN106146671B/zh active Active
- 2009-12-09 ES ES09836751.9T patent/ES2582005T3/es active Active
- 2009-12-09 SI SI200932062T patent/SI3067064T1/sl unknown
- 2009-12-09 CA CA2746228A patent/CA2746228C/en active Active
- 2009-12-09 RU RU2011128371/10A patent/RU2531510C2/ru active
- 2009-12-09 HU HUE09836751A patent/HUE029037T2/en unknown
- 2009-12-09 US US12/633,995 patent/US8715692B2/en active Active
- 2009-12-09 PT PT161660337T patent/PT3067064T/pt unknown
- 2009-12-09 KR KR1020117015954A patent/KR101691574B1/ko active IP Right Grant
- 2009-12-09 EP EP09836751.9A patent/EP2370099B1/en active Active
-
2011
- 2011-06-09 IL IL213450A patent/IL213450B/en active IP Right Grant
-
2012
- 2012-03-06 HK HK12102267.8A patent/HK1161690A1/zh unknown
-
2014
- 2014-03-21 US US14/221,675 patent/US9675685B2/en active Active
-
2015
- 2015-06-04 US US14/730,805 patent/US9731000B2/en active Active
- 2015-06-04 US US14/730,809 patent/US9717786B2/en active Active
- 2015-06-19 JP JP2015124158A patent/JP6162751B2/ja active Active
- 2015-08-28 US US14/839,247 patent/US10022437B2/en active Active
-
2016
- 2016-07-11 CY CY20161100652T patent/CY1117757T1/el unknown
- 2016-07-13 HR HRP20160859TT patent/HRP20160859T1/hr unknown
- 2016-08-18 IL IL247341A patent/IL247341B/en active IP Right Grant
-
2017
- 2017-06-15 JP JP2017118032A patent/JP6462048B2/ja active Active
-
2018
- 2018-06-15 US US16/009,257 patent/US11052146B2/en active Active
- 2018-12-26 JP JP2018242108A patent/JP6782289B2/ja active Active
-
2020
- 2020-05-29 CY CY20201100490T patent/CY1123152T1/el unknown
- 2020-06-02 HR HRP20200871TT patent/HRP20200871T1/hr unknown
-
2022
- 2022-08-10 US US17/818,887 patent/US20230293667A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3067064T3 (da) | Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf | |
DK2320911T3 (da) | Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf | |
DK2222675T3 (da) | 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse | |
DK2139987T5 (da) | Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser | |
DK2346551T3 (da) | Cylinderampul og kanylesystem til denne | |
DK2252633T3 (da) | Anti-TrkA antistoffer og derivater deraf | |
DK2147315T3 (da) | Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf | |
DK2337568T3 (da) | Fremgangsmåder og midler til blødvævsteknologi | |
DK2120591T3 (da) | Ny drikkeyoghurt og fremgangsmåde til fremstilling deraf | |
DK2418941T3 (da) | Enzymindgivelsessystemer og fremgangsmåder til fremstilling og anvendelse | |
DK2209375T3 (da) | Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf | |
FI20085334A (fi) | Harjoitusmenetelmä ja -järjestelmä | |
BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
DK3092901T3 (da) | Quinolonanaloger og fremgangsmåder relateret dertil | |
DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
DK2467173T3 (da) | Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf | |
DK3118220T3 (da) | Protein | |
DK2337837T3 (da) | Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf | |
BRPI0908379A2 (pt) | sistemas e métodos para obter dentaduras customizadas | |
DK2240203T3 (da) | Alfa5-beta1-antistoffer og deres anvendelser | |
DK2358669T3 (da) | Alpha-keto-persyrer og fremgangsmåder til fremstilling og anvendelse heraf | |
DK3560915T3 (da) | Polypeptider med oxidoreduktaseaktivitet og anvendelser deraf | |
DK2229360T3 (da) | Indolinonderivater og fremgangsmåde til deres fremstilling | |
DK3338790T3 (da) | Oligopeptid-forbindelser og anvendelser deraf | |
DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner |